Valuation: Astellas Pharma Inc.

Market Cap 3,945B 24.75B 21.52B 20.03B 18.39B 34.73B 2,363B 35.27B 236B 92.66B 1,176B 92.97B 90.93B P/E 2027 *
11.5x
P/E 2028 * 11.9x
Enterprise Value 3,815B 23.94B 20.81B 19.37B 17.78B 33.58B 2,285B 34.1B 228B 89.61B 1,138B 89.9B 87.93B EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.67x
Free-Float
97.66%
Yield 2027 *
3.65%
Yield 2028 * 3.77%
1 day-4.79%
1 week+3.98%
1 month+2.69%
3 months-3.99%
6 months-0.94%
Current year+3.31%
1 week 13.37
Extreme 13.3675
14.47
1 month 13.03
Extreme 13.03
14.47
Current year 12.82
Extreme 12.8175
17.35
1 year 10.03
Extreme 10.03
17.35
3 years 8.37
Extreme 8.37
17.35
5 years 8.37
Extreme 8.37
18.18
10 years 8.37
Extreme 8.37
18.46
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2023
Director of Finance/CFO 54 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 63 01/06/2019
Director/Board Member 58 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.79%+3.98% - - 25.7B
-0.53%-3.95%+55.23%+152.74% 1,030B
+0.21%-2.68%+55.61%+53.02% 617B
-2.51%-3.25%+32.76%+67.76% 455B
+0.06%-0.42%+37.53%+30.67% 350B
-0.14%-0.24%+34.41%+39.01% 299B
-0.69%-0.30%+11.55%+12.93% 265B
-7.37%-4.40%-2.54%-43.87% 225B
-0.64%+2.43%+30.52%+64.49% 209B
-0.82%+0.70%+15.96%+71.01% 163B
Average -1.72%+1.38%+30.11%+49.75% 401.41B
Weighted average by Cap. -1.05%-0.11%+39.02%+72.47%

Financials

2027 *2028 *
Net sales 2,260B 14.18B 12.33B 11.47B 10.53B 19.89B 1,354B 20.2B 135B 53.07B 674B 53.25B 52.08B 2,079B 13.05B 11.34B 10.56B 9.69B 18.3B 1,245B 18.59B 124B 48.83B 620B 49B 47.92B
Net income 343B 2.15B 1.87B 1.74B 1.6B 3.02B 205B 3.06B 20.5B 8.05B 102B 8.07B 7.9B 331B 2.08B 1.8B 1.68B 1.54B 2.91B 198B 2.96B 19.8B 7.77B 98.64B 7.8B 7.62B
Net Debt -130B -816M -710M -660M -606M -1.15B -77.92B -1.16B -7.78B -3.06B -38.79B -3.07B -3B -472B -2.96B -2.58B -2.4B -2.2B -4.16B -283B -4.22B -28.27B -11.09B -141B -11.13B -10.89B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
31/07/26 USD 13.73 -4.79% 148,959
30/07/26 USD 14.42 +3.37% 124,999
29/07/26 USD 13.95 +2.20% 77,611
28/07/26 USD 13.65 +1.78% 130,246
27/07/26 USD 13.41 +1.56% 175,779
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2,202.00JPY
Average target price
2,388.46JPY
Spread / Average Target
+8.47%

Quarterly revenue - Rate of surprise